Cyclacel Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CYCC

*Your capital is at risk

$6.37

+0 (+0%)

At Close: Dec 10, 2025

Cyclacel Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 27.27. In total, the insiders bought 412.36M and sold 390.43M CYCC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	27.27
● Buy	412.36M shares
● Sell	390.43M shares
88% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 26, 2025 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 27.27. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 29, 2025 Buy	Cyclacel Common Stock, par value $0.0001 per share	Ho Kee Wee 10 Percent Owner	10% Owner	0 Value: $0
Apr 29, 2025 Buy	Cyclacel Common Stock, par value $0.0001 per share	Ho Jien Shiung 10 Percent Owner	10% Owner	0 Value: $0
Apr 29, 2025 Buy	Cyclacel Common Stock, par value $0.0001 per share	Tan Kok Hui 10 Percent Owner	10% Owner	0 Value: $0
Apr 29, 2025 Buy	Cyclacel Common Stock, par value $0.0001 per share	Tan Kok Hui 10 Percent Owner	10% Owner	0 Value: $0
Apr 29, 2025 Buy	Cyclacel Common Stock, par value $0.0001 per share	Suria Sukses Engineering Sdn Bhd 10 Percent Owner	10% Owner	0 Value: $0
Apr 29, 2025 Buy	Cyclacel Common Stock, par value $0.0001 per share	Suria Sukses Engineering Sdn Bhd 10 Percent Owner	10% Owner	0 Value: $0
Apr 02, 2025 Buy	No Securities Beneficially Owned	Laurduraj Inigo Angel Director	Director	0 Value: $0
Apr 02, 2025 Buy	No Securities Beneficially Owned	Nair Krishnan Satis Waran Director	Director	0 Value: $0
Apr 02, 2025 Buy	No Securities Beneficially Owned	Nair Krishnan Satis Waran Director	Director	0 Value: $0
Apr 02, 2025 Buy	No Securities Beneficially Owned	Laurduraj Inigo Angel Director	Director	0 Value: $0
Feb 26, 2025 Buy	Non-Qualified Stock Option (Right to Buy) A-Award	Natan David Director	Director	700 000 Value: $231.0K
Feb 26, 2025 Buy	Common Stock M-Exempt	Lazar David E. Interim CEO	CEO / President	191 978 820 Value: $61.6M
Feb 26, 2025 Buy	Common Stock M-Exempt	Lazar David E. Interim CEO	CEO / President	2 650 000 Value: $850.7K
Feb 26, 2025 Buy	Series D Convertible Preferred Stock M-Exempt	Lazar David E. Interim CEO	CEO / President	1 745 262 Value: $560.2K
Feb 26, 2025 Sell	Common Stock S-Sale	Lazar David E. Interim CEO	CEO / President	194 628 820 Value: $5.51M
Feb 26, 2025 Buy	Series C Convertible Preferred Stock M-Exempt	Lazar David E. Interim CEO	CEO / President	1 000 000 Value: $321.0K
Feb 26, 2025 Buy	Non-Qualified Stock Option (Right to Buy) A-Award	Ben-tzvi Avraham Director	Director	700 000 Value: $231.0K
Feb 26, 2025 Buy	Common Stock	Doris Wong Sing Ee Chief Executive Officer	CEO / President	0 Value: $0
Feb 26, 2025 Buy	No Securities Beneficially Owned	Chong Kwang Fock Director	Director	0 Value: $0
Feb 26, 2025 Buy	No Securities Beneficially Owned	Kiu Cu Seng CFO And Secretary	C-Suite Officer	0 Value: $0
Feb 26, 2025 Buy	No Securities Beneficially Owned	Kiu Cu Seng CFO And Secretary	C-Suite Officer	0 Value: $0
Feb 26, 2025 Buy	No Securities Beneficially Owned	Chong Kwang Fock Director	Director	0 Value: $0
Feb 26, 2025 Buy	Common Stock	Doris Wong Sing Ee Chief Executive Officer	CEO / President	0 Value: $0
Feb 26, 2025 Buy	Non-Qualified Stock Option (Right to Buy) A-Award	Ben-tzvi Avraham Director	Director	700 000 Value: $231.0K
Feb 26, 2025 Buy	Series C Convertible Preferred Stock M-Exempt	Lazar David E. Interim CEO	CEO / President	1 000 000 Value: $321.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYCLACEL PHARMACEUTICALS

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...

Read Full Profile Here